Zoetis Inc. Quarterly Report for Q1 Ended Mar 31, 2021

Summary

Zoetis Inc. reported strong financial performance for the first quarter of 2021, with total revenue increasing by 22% to $1.87 billion, driven by robust operational growth of 21%. This growth was largely fueled by volume increases in both established and new products, particularly in the companion animal segment. Net income attributable to Zoetis Inc. saw a significant jump of 32% to $559 million, or $1.17 per diluted share, reflecting improved operational efficiencies and favorable product mix. The company's performance was strong across both its U.S. and International segments. The U.S. segment grew revenue by 19%, primarily driven by companion animal products like parasiticides, while the International segment saw a 27% revenue increase, also boosted by companion animal products and recovering livestock markets, especially in China. Zoetis continues to invest in research and development, with R&D expenses increasing by 10% to support future growth. The company also maintained a healthy liquidity position with $3.6 billion in cash and cash equivalents.

Key Highlights

• 1Revenue increased by 22% to $1.87 billion in Q1 2021, with 21% driven by operational growth.
• 2Net income attributable to Zoetis Inc. grew by 32% to $559 million.
• 3Diluted EPS increased by 32% to $1.17 compared to the prior year period.
• 4Companion animal products were a key growth driver, with significant contributions from parasiticides like Simparica Trio.
• 5The International segment showed strong revenue growth of 27%, benefiting from expanding herd production in China and improved export conditions.
• 6Cost of sales as a percentage of revenue improved to 29.3% from 29.9% due to favorable product mix.
• 7Zoetis resumed its share repurchase program in January 2021, with $1.2 billion remaining authorization as of March 31, 2021.

Frequently Asked Questions